

1.	<p>Treatment & Condition</p> <p>Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer</p>																								
2.	<p>Associated appraisal body & Summary of ruling</p> <p>NICE Technology Appraisal guidance TA654 (October 2020)</p> <p>Osimertinib is recommended, within its marketing authorisation, as an option for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) in adults. It is recommended only if the company provides osimertinib according to the commercial arrangement.</p>																								
3.	<p>Number of people in Northern Ireland expected to take up service/therapy</p> <p>According to the NICE Resource Impact Template that accompanies TA654, expected patient numbers are as follows:</p> <table border="1" data-bbox="261 994 1445 1274"> <thead> <tr> <th data-bbox="261 994 746 1095">People having osimertinib as a first-line treatment in Northern Ireland</th> <th data-bbox="746 994 895 1095">Year 1 2020/21</th> <th data-bbox="895 994 1027 1095">Year 2 2021/22</th> <th data-bbox="1027 994 1160 1095">Year 3 2022/23</th> <th data-bbox="1160 994 1292 1095">Year 4 2023/24</th> <th data-bbox="1292 994 1445 1095">Year 5 2024/25</th> </tr> </thead> <tbody> <tr> <td data-bbox="261 1095 746 1167">People who start osimertinib - first year of treatment</td> <td data-bbox="746 1095 895 1167">9</td> <td data-bbox="895 1095 1027 1167">19</td> <td data-bbox="1027 1095 1160 1167">28</td> <td data-bbox="1160 1095 1292 1167">38</td> <td data-bbox="1292 1095 1445 1167">38</td> </tr> <tr> <td data-bbox="261 1167 746 1238">People who continue osimertinib - 2nd year of treatment</td> <td data-bbox="746 1167 895 1238"></td> <td data-bbox="895 1167 1027 1238">9</td> <td data-bbox="1027 1167 1160 1238">19</td> <td data-bbox="1160 1167 1292 1238">28</td> <td data-bbox="1292 1167 1445 1238">38</td> </tr> <tr> <td data-bbox="261 1238 746 1274">Total</td> <td data-bbox="746 1238 895 1274">9</td> <td data-bbox="895 1238 1027 1274">28</td> <td data-bbox="1027 1238 1160 1274">47</td> <td data-bbox="1160 1238 1292 1274">66</td> <td data-bbox="1292 1238 1445 1274">76</td> </tr> </tbody> </table>	People having osimertinib as a first-line treatment in Northern Ireland	Year 1 2020/21	Year 2 2021/22	Year 3 2022/23	Year 4 2023/24	Year 5 2024/25	People who start osimertinib - first year of treatment	9	19	28	38	38	People who continue osimertinib - 2nd year of treatment		9	19	28	38	Total	9	28	47	66	76
People having osimertinib as a first-line treatment in Northern Ireland	Year 1 2020/21	Year 2 2021/22	Year 3 2022/23	Year 4 2023/24	Year 5 2024/25																				
People who start osimertinib - first year of treatment	9	19	28	38	38																				
People who continue osimertinib - 2nd year of treatment		9	19	28	38																				
Total	9	28	47	66	76																				
4.	<p>Patient Access Scheme Availability</p> <p>(<u>Yes</u>/No)</p> <p>The company (Astra Zeneca) has a commercial arrangement that makes osimertinib available to the NHS with a discount. The size of the discount is commercial in confidence.</p>																								
5.	<p>Infrastructure Requirements</p> <p>Any additional infrastructure costs associated with the introduction of new cancer therapies will be dealt with as part of the routine commissioning process.</p>																								
6.	<p>Expected implementation period</p> <p>There is no impediment to immediate implementation for new patients.</p>																								
7.	<p>Commissioning arrangements</p> <p>This regimen will be formally commissioned by the HSCB/PHA via the Specialist Services Commissioning Team initially on a cost-per-case (CPC) basis. Thereafter, numbers of patients who received or are receiving treatment will be reviewed and</p>																								

	consideration will be given to moving to recurrent funding to support this regimen
8.	Monitoring arrangements The HSCB cost per case process will generate quarterly reports on the number of applications.
9.	DoH (NI) Legislative/Policy Caveats This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.